These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents. Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269 [TBL] [Abstract][Full Text] [Related]
6. Toxicity of Carlina Oxide-A Natural Polyacetylene from the Wnorowski A; Wnorowska S; Wojas-Krawczyk K; Grenda A; Staniak M; Michalak A; Woźniak S; Matosiuk D; Biała G; Wójciak M; Sowa I; Krawczyk P; Strzemski M Toxins (Basel); 2020 Apr; 12(4):. PubMed ID: 32283677 [TBL] [Abstract][Full Text] [Related]
7. Identification of potential plant bioactive as SARS-CoV-2 Spike protein and human ACE2 fusion inhibitors. Singh R; Bhardwaj VK; Sharma J; Kumar D; Purohit R Comput Biol Med; 2021 Sep; 136():104631. PubMed ID: 34273770 [TBL] [Abstract][Full Text] [Related]
8. Mutational landscape and in silico structure models of SARS-CoV-2 spike receptor binding domain reveal key molecular determinants for virus-host interaction. Nelson-Sathi S; Umasankar PK; Sreekumar E; Nair RR; Joseph I; Nori SRC; Philip JS; Prasad R; Navyasree KV; Ramesh S; Pillai H; Ghosh S; Santosh Kumar TR; Pillai MR BMC Mol Cell Biol; 2022 Jan; 23(1):2. PubMed ID: 34991443 [TBL] [Abstract][Full Text] [Related]
9. Tinocordiside from Balkrishna A; Pokhrel S; Varshney A Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372 [TBL] [Abstract][Full Text] [Related]
10. Use of hyphenated analytical techniques to identify the bioactive constituents of Gunnera perpensa L., a South African medicinal plant, which potently inhibit SARS-CoV-2 spike glycoprotein-host ACE2 binding. Invernizzi L; Moyo P; Cassel J; Isaacs FJ; Salvino JM; Montaner LJ; Tietjen I; Maharaj V Anal Bioanal Chem; 2022 May; 414(13):3971-3985. PubMed ID: 35419694 [TBL] [Abstract][Full Text] [Related]
11. Interactions of angiotensin-converting enzyme-2 (ACE2) and SARS-CoV-2 spike receptor-binding domain (RBD): a structural perspective. Borkotoky S; Dey D; Hazarika Z Mol Biol Rep; 2023 Mar; 50(3):2713-2721. PubMed ID: 36562937 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19). Nayak SK Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074 [TBL] [Abstract][Full Text] [Related]
13. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study. Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454 [TBL] [Abstract][Full Text] [Related]
14. Truncated human angiotensin converting enzyme 2; a potential inhibitor of SARS-CoV-2 spike glycoprotein and potent COVID-19 therapeutic agent. Basit A; Ali T; Rehman SU J Biomol Struct Dyn; 2021 Jul; 39(10):3605-3614. PubMed ID: 32396773 [TBL] [Abstract][Full Text] [Related]
15. Biomechanical characterization of SARS-CoV-2 spike RBD and human ACE2 protein-protein interaction. Cao W; Dong C; Kim S; Hou D; Tai W; Du L; Im W; Zhang XF Biophys J; 2021 Mar; 120(6):1011-1019. PubMed ID: 33607086 [TBL] [Abstract][Full Text] [Related]
16. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
17. Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. Ridgway H; Chasapis CT; Kelaidonis K; Ligielli I; Moore GJ; Gadanec LK; Zulli A; Apostolopoulos V; Mavromoustakos T; Matsoukas JM Viruses; 2022 May; 14(5):. PubMed ID: 35632769 [TBL] [Abstract][Full Text] [Related]
18. An Stalin A; Lin D; Senthamarai Kannan B; Feng Y; Wang Y; Zhao W; Ignacimuthu S; Wei DQ; Chen Y J Biomol Struct Dyn; 2022 Oct; 40(16):7408-7423. PubMed ID: 33685364 [TBL] [Abstract][Full Text] [Related]
19. In silico investigations of heparin binding to SARS-CoV-2 variants with a focus at the RBD/ACE2 interface. Ali N; Khan R; AlAsmari AF; Kumar V Process Biochem; 2022 Apr; 115():70-79. PubMed ID: 35194375 [TBL] [Abstract][Full Text] [Related]